Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 12:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 659 matching trials from the live ClinicalTrials.gov search.
Conditions
Diabetes Mellitus, Type 2
Interventions
SGLT2, Metformin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Parkinson Disease
Interventions
Liraglutide, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
25 Years to 85 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Insulin Resistance
Interventions
Last 5 amino acids of GLP-1, placebo saline
Drug
Lead sponsor
Elahi, Dariush, PhD
Individual
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Terminated Phase 2 Interventional Results available

Efficacy of Liraglutide Therapy in Patients With IPAA

NCT04763564
Conditions
Pouchitis, Irritable Pouch Syndrome
Interventions
Liraglutide Pen Injector, Placebo Pen Injector
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Comparing Facial Aging Between Identical Twins With 3D Imaging

NCT07760532
Conditions
Facial Skin Aging, Facial Volume Loss, Wrinkle Appearance
Interventions
GLP-1 Receptor Agonists
Drug
Lead sponsor
Ponsky Facial Aesthetics And Plastic Surgery, Llc
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Beachwood, Ohio
Conditions
Diabetes Mellitus, Type 2
Interventions
Empagliflozin, DPP-4 inhibitor, GLP-1 receptor agonist
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
230,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Obesity and Obesity-related Medical Conditions, Bariatric Surgery
Interventions
tirzepatide, Standard of Care
Drug · Behavioral
Lead sponsor
Marlene Starr
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lexington, Kentucky
Conditions
Obesity
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 60 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Conditions
Congestive Heart Failure
Interventions
AC2592, placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
29
States / cities
Beverly Hills, California • Mission Viejo, California • New Haven, Connecticut + 26 more
Completed Not applicable Interventional Accepts healthy volunteers

The Influence of Breakfast on Hormone Responses and Cognitive Performance

NCT03005951
Conditions
Insulin Resistance
Interventions
A= Yes Breakfast, B=No Breakfast
Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
13 Years to 18 Years · Male only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Obesity
Interventions
bremelanotide, tirzepatide
Drug
Lead sponsor
Palatin Technologies, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
DeLand, Florida • Oklahoma City, Oklahoma • North Charleston, South Carolina + 1 more
Conditions
HIV Infection, Diabetes Mellitus Type 2, Obesity, Overweight, Metabolic Syndrome
Interventions
Liraglutide
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Not applicable Interventional Accepts healthy volunteers

Avocado and Postprandial Responses

NCT06818032
Conditions
Healthy, Healthy Volunteer, Healthy Volunteers, Healthy Adult, Healthy Male and Female Subjects, Healthy Subjects, Healthy Volunteers Only, Healthy Non-smokers
Interventions
Negative control, Avocado, Fat and fiber addition
Other
Lead sponsor
University of Vermont Medical Center
Other
Eligibility
21 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Burlington, Vermont
Conditions
Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions
Tirzepatide, Placebo
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
40 Years and older
Enrollment
731 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
54
States / cities
Huntsville, Alabama • Beverly Hills, California • Covina, California + 51 more
Conditions
Obesity, Metabolic Disease
Interventions
Standard Care, Culturally-tailored dietary and behavioral intensive lifestyle intervention, Placebo, Tirzepatide
Behavioral · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
21 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Santa Barbara, California
Conditions
Type 1 Diabetes, Obesity, Overweight
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
905 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
31
States / cities
Santa Barbara, California • Santa Clarita, California • Aurora, Colorado + 27 more
Conditions
Spinal Cord Injuries, Insulin Resistance, Pre Diabetes, Obesity
Interventions
Semaglutide 1MG Injection [Ozempic], No Intervention
Drug · Other
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 69 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
West Orange, New Jersey
Conditions
Post Bariatric Hypoglycemia
Interventions
Lyo avexitide, Liq avexitide
Drug
Lead sponsor
Tracey McLaughlin
Other
Eligibility
18 Years to 70 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Stanford, California
Conditions
Type 2 Diabetes
Interventions
Roflumilast, Alogliptin, Exenatide, Placebo to roflumilast, Placebo to alogliptin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
2
States / cities
Chula Vista, California • Orlando, Florida
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec, placebo, liraglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
67
States / cities
Anaheim, California • Concord, California • Escondido, California + 59 more
Completed Early Phase 1 Interventional Accepts healthy volunteers

Role of Glucagon In Glucose Control in Cystic Fibrosis Related Diabetes

NCT02398383
Conditions
Cystic Fibrosis, Cystic Fibrosis Related Diabetes
Interventions
Oral Glucose Tolerance Test, Mixed Meal Tolerance Test, Hypoglycemic Clamp
Other
Lead sponsor
Yale University
Other
Eligibility
12 Years to 45 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Diabetes Mellitus, Type 2, HFpEF - Heart Failure With Preserved Ejection Fraction
Interventions
Tirzepatide, Semaglutide
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
28,118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Boston, Massachusetts
Active, not recruiting Phase 2 Interventional

Aleniglipron Phase 2 Body Composition Study

NCT07169942
Conditions
Obesity, Overweight, or Chronic Weight Management
Interventions
aleniglipron or placebo
Drug
Lead sponsor
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Industry
Eligibility
18 Years to 79 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
11
States / cities
Phoenix, Arizona • Chicago, Illinois • Richfield, Minnesota + 8 more
Conditions
Acute Heart Failure
Interventions
Liraglutide, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
25
States / cities
Newark, Delaware • Atlanta, Georgia • Chicago, Illinois + 14 more